Drugs / SKB118
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07586943 | Jun 2026 → Dec 2029 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07854509 | Oct 2026 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07697586 | Aug 2026 → Aug 2028 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody kelun-biotech.com ↗
We are pleased to see the approval of the IND application for SKB118 in China, which marks the simultaneous advancement of clinical development in China and globally. |
| 2026-01-05 | Crescent Biopharma, Inc. | Regulatory Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors crescentbiopharma.com ↗ |
| 2026-01-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA kelun-biotech.com ↗
The IND application for SKB118/CR-001 has been cleared by the U.S. Food and Drug Administration (FDA) with a global Phase I/II clinical trial for the treatment of advanced solid tumors is set to commence shortly. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody kelun-biotech.com ↗ |
| 2026-05-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody kelun-biotech.com ↗ |
| 2026-01-05 | Crescent Biopharma, Inc. | Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors crescentbiopharma.com ↗ |
| 2026-01-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA kelun-biotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07586943 ↗ |
| Route | Intravenous | “iv drip” NCT07586943 ↗ |